Description
Bravecto Chews For Dogs 9.9-22 Lbs (4.5-10 Kg) contains 250 mg fluralaner per chew, calibrated to deliver a minimum of 11.4 mg/lb (25 mg/kg) body weight across the full weight range. Fluralaner belongs to the isoxazoline class and acts systemically by inhibiting arthropod GABA-gated and glutamate-gated chloride channels, killing parasites through the dog’s bloodstream rather than on skin contact. Each chew provides 12 weeks of flea and tick coverage for four tick species, with an 8-week window for lone star tick (Amblyomma americanum) specifically.
Recommended for:
Dogs and puppies weighing 9.9–22 lbs (4.5–10 kg), aged 6 months and older.
Indication/Coverage:
For dogs suffering from, or at risk from, flea and tick infestations, Bravecto Chews 9.9-22 Lbs (4.5-10 Kg) addresses the following parasites and conditions:
- Flea treatment and prevention: Kills adult cat fleas (Ctenocephalides felis) and dog fleas (Ctenocephalides canis) within 8 hours of attachment, with persistent activity sustained across a full 12-week dosing interval.
- Black-legged tick (deer tick) control: Treatment and control of Ixodes scapularis infestations for 12 weeks; this species is the primary vector of Lyme disease across the northeastern and upper midwestern United States.
- American dog tick control: Treatment and control of Dermacentor variabilis for 12 weeks; this species transmits Rocky Mountain spotted fever.
- Brown dog tick control: Treatment and control of Rhipicephalus sanguineus for 12 weeks, with efficacy confirmed at the adult stage at 48 hours post-infestation.
- Asian longhorned tick control: Treatment and control of Haemaphysalis longicornis for 12 weeks; an invasive species now established across multiple U.S. states, with efficacy confirmed at 48 hours post-infestation.
- Lone star tick control: Treatment and control of Amblyomma americanum for 8 weeks in dogs 6 months of age and older; fluralaner does not sustain 90% or greater efficacy against this species beyond week 8, and is not labeled for puppies under 6 months for this indication.
- Flea Allergy Dermatitis (FAD) management: Eliminates the flea populations responsible for triggering allergic responses in sensitized dogs, making fluralaner a clinically appropriate component of an FAD control strategy when flea source elimination is the primary objective.
- Environmental flea cycle disruption: Newly emerged fleas that feed on a treated dog are killed before producing viable eggs, interrupting reinfestation in the dog’s immediate environment.
- Reduction of tapeworm and tick-borne disease risk: Controlling flea and tick populations removes the intermediate hosts and vectors responsible for transmitting Dipylidium caninum (tapeworm) and tick-borne pathogens including Borrelia burgdorferi and Rickettsia rickettsii.
Key Benefits:
The following characteristics are drawn directly from the FDA-approved label for Bravecto Chews (fluralaner) 250 mg.
- Covers the full medium-small range: Labeled for dogs from 9.9 lbs (4.5 kg) through 22 lbs (10 kg), encompassing breeds such as Beagles, Cavalier King Charles Spaniels, and Miniature Schnauzers at typical adult weight.
- Five-species tick coverage: A single chew addresses five distinct tick species including the Lyme disease vector Ixodes scapularis and the Rocky Mountain spotted fever vector Dermacentor variabilis, covering the tick spectrum relevant to most U.S. geographic regions.
- Systemic isoxazoline mechanism: Fluralaner inhibits arthropod GABA-gated and glutamate-gated chloride channels, causing irreversible neural excitation and death in parasites that feed on the dog’s blood, without requiring surface contact prior to kill.
- Flea kill within 8 hours: Adult fleas are killed within 8 hours of attachment, limiting the feeding time available for flea allergy sensitization and egg deposition before the parasite dies.
- 12-week single-dose duration: One 250 mg chew covers a full 12-week protection window for fleas and four tick species, reducing the total number of annual doses required compared to monthly oral parasiticides.
- Oral format for coat-sensitive dogs: Administered as a flavored chew rather than a topical spot-on, this formulation is appropriate for dogs with dermatological conditions at the application site or in households where topical residue contact with children or other pets is a concern.
- FAD lesion resolution: In the U.S. field study, dogs presenting with flea allergy dermatitis showed measurable improvement in erythema, alopecia, papules, scales, crusts, and excoriation as a direct consequence of flea population elimination.
- Food-dependent bioavailability: Fluralaner reaches peak plasma concentration between 2 hours and 3 days post-administration. Reduced bioavailability in the fasted state means administering with food is necessary to achieve the labeled therapeutic concentration.
Caution:
Hazards to Humans
Bravecto Chews are not for human use. Keep the product in its original blister packaging and out of reach of children until the moment of administration. Do not eat, drink, or smoke while handling the chew. Wash hands thoroughly with soap and water immediately after giving the dose to the dog.
Hazards to Domestic Animals
Bravecto Chews are for oral administration only. The 9.9–22 lb variant is labeled for dogs and puppies weighing at least 9.9 lbs (4.5 kg) and aged 6 months or older. Dogs below this weight threshold or age requirement should not receive this tablet; consult a veterinarian before use in debilitated, aged, pregnant, or lactating animals. Fluralaner belongs to the isoxazoline class, associated with neurologic adverse reactions including tremors, ataxia, and seizures, even in dogs with no prior seizure history; use with caution in dogs with a history of seizures or neurological disorders. Adverse events following use in breeding females have been reported in post-approval surveillance. Verify any concurrent medication combinations with a veterinarian before the first dose.
Possible Side Effects:
Monitor your dog in the hours following administration of Bravecto Chews, particularly after the first dose.
The following reactions were recorded in the controlled U.S. field study (182-day observation period, n=224 dogs) and in post-approval adverse drug experience reporting to the FDA/CVM:
- Vomiting: Reported in 7.1% of dogs in the Bravecto field study group; the most frequently observed GI sign, generally transient and self-limiting.
- Decreased appetite: Reported in 6.7% of dogs receiving Bravecto, and absent in the active control group, indicating a product-specific association at this frequency.
- Lethargy: Reported in 5.4% of field study dogs; resolved without medical intervention in the majority of cases.
- Diarrhea: Reported in 4.9% of dogs; post-approval reports include bloody diarrhea in a subset of cases.
- Polydipsia: Reported in 1.8% of Bravecto-group dogs.
- Flatulence: Reported in 1.3% of dogs.
- Neurologic signs: Post-approval reporting includes tremors, ataxia, and seizures. These have occurred in dogs with no prior seizure history receiving isoxazoline-class drugs.
- Dermal and allergic reactions: Post-approval reporting includes pruritus, hives, swelling, erythema, and dermatitis presenting as crusts, pustules, or rash.
If any of these signs develop after administration, contact your veterinarian for advice and evaluation. The dog should be examined before the next scheduled dose if any neurologic or allergic signs have occurred.














We’ve seen a noticeable decrease in our dog’s scratching since starting this treatment.
These chewables have been a game-changer for our outdoor-loving dog.
My dog used to suffer from fleas and ticks, but not anymore. This product works great and we’ve had no side effects.
This chewable tablet is a lifesaver. It’s easy to give and keeps all the nasty fleas and ticks away from my dog.
We’ve been using this product for a few months now, and it’s made a world of difference. Our dog is healthier and more active than ever.